

ASX Release

Anatara retains global market for Detach[®]

BRISBANE & MELBOURNE, 14th June 2019: Anatara Lifesciences (ASX:ANR) announces that Zoetis Inc. has given notice of termination of the exclusive worldwide license of Detach[®] for livestock and horses. Zoetis made a portfolio decision not to continue with the pursuit of this asset.

Scour (diarrhoea) in piglets is an expensive, debilitating and in some cases, life-threatening condition. Increasing survivability and providing health benefits to pre-weaning piglets has been at the core of the development of Detach[®] since the Company was listed in 2014.

In October last year, Anatara announced that the Australian Pesticides and Veterinary Medicines Authority (APVMA) had registered Detach[®] with the approved label, *“To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets”*.

Anatara will now re-evaluate commercialisation opportunities for Detach[®] including options for launch of the APVMA approved product in Australia, regulatory approval of this product in overseas markets, development of this product for species other than piglets and, global or regional licensing of Detach[®].

Prior to executing the exclusive license agreement with Zoetis Inc., Anatara engaged with >10 top multi-national animal health companies. Anatara will now undertake a strategic review and provide an update to the market in the coming weeks.

Anatara continues to progress development of its dietary supplement for sufferers of gastrointestinal conditions such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Eleven percent of the global population is affected by IBS¹, with 5 million IBD sufferers worldwide². These disorders are multicausal and no single treatment is effective for all sufferers. Over 50% of IBS³ and IBD⁴ patients try complementary and alternative medicines, in the hope of effectively managing their disorder.

¹ Clinical Gastroenterology and Hepatology 2012: 10, 712-721

² Gastroenterology 2017: 152:415-429

³ Gastroenterology 2017: 152:415-429

⁴ World J. Gastroenterol 2014: 346-362

For more information please contact:

Investor and Media inquiries	
Steven Lydeamore Chief Executive Officer Anatara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Sue MacLeman Chair Anatara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anatara.com

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

